Medisix Therapeutics Pte. Ltd., of Singapore, signed an exclusive licensing agreement with the National University of Singapore that included undisclosed patent and technology rights to develop certain intellectual property for commercial applications. Medisix is developing chimeric antigen receptor T cells that target T-cell lymphoma and leukemia.